EUVIMEDEUVIMED entdecken
Crossref

Sustained Immune Control in HBeAg-Positive Patients who Switched from Entecavir Therapy to Pegylated Interferon-α2a: 1 Year follow-up of the OSST Study

Meifang Han, Jiaji Jiang, Jinlin Hou, Deming Tan, Yongtao Sun, Mianzhi Zhao, Qin Ning

Antiviral Therapy · 2016-05 · 21 (4) · 337-344

DOI: 10.3851/imp3019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antiviral Therapy, online erschienen am 01.05.2015. Verfasst von Meifang Han und 6 weiteren Autor:innen. Beteiligte Einrichtung: Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the OSST study, hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients who switched from long-term entecavir (ETV) therapy to pegylated interferon-α2a (PEG-IFN-α2a; 40 kDa) achieved higher rates of HBeAg seroconversion and hepatitis B surface antigen (HBsAg) loss than those who continued ETV. Herein we report the sustainability of serological responses during 1 year of untreated follow-up in patients who switched from ETV to PEG-IFN-α2a therapy.

Methods

A total of 62 patients who completed 48 weeks of PEG-IFN-α2a therapy were followed-up for 48 weeks off treatment. Primary end points were HBeAg seroconversion and maintenance of HBeAg seroconversion at 48 weeks post-treatment. Secondary end points included HBsAg loss, HBV DNA

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdultAntiviral AgentsDrug Administration ScheduleFemaleGuanineHepatitis B e AntigensHepatitis B, ChronicHumansInterferon-alphaMalePolyethylene GlycolsRecombinant Proteins

Substanzen

Antiviral AgentsHepatitis B e AntigensInterferon-alphaRecombinant ProteinsPolyethylene GlycolsentecavirGuaninepeginterferon alfa-2a

Autor:innen und Institutionen

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Zitieren

APA

Han, M., Jiang, J., Hou, J., Tan, D., Sun, Y., Zhao, M., & Ning, Q. (2016). Sustained Immune Control in HBeAg-Positive Patients who Switched from Entecavir Therapy to Pegylated Interferon-α2a: 1 Year follow-up of the OSST Study. Antiviral Therapy, 21(4), 337-344. https://doi.org/10.3851/imp3019

Vancouver

Han M, Jiang J, Hou J, Tan D, Sun Y, Zhao M, et al. Sustained Immune Control in HBeAg-Positive Patients who Switched from Entecavir Therapy to Pegylated Interferon-α2a: 1 Year follow-up of the OSST Study. Antiviral Therapy. 2016;21(4):337-344. doi:10.3851/imp3019

BibTeX
@article{Han2016,
  author = {Han, Meifang and Jiang, Jiaji and Hou, Jinlin and Tan, Deming and Sun, Yongtao and Zhao, Mianzhi and Ning, Qin},
  title = {Sustained Immune Control in HBeAg-Positive Patients who Switched from Entecavir Therapy to Pegylated Interferon-α2a: 1 Year follow-up of the OSST Study},
  journal = {Antiviral Therapy},
  year = {2016},
  volume = {21},
  number = {4},
  pages = {337--344},
  doi = {10.3851/imp3019}
}
Kostenlos starten →